Objective-To assess the effects of calcium channel blockers on development of infarcts, reinfarction, and mortality.
Although there are substantial similarities in their mechanism of action, the various calcium channel blockers differ somewhat in their ancillary properties.2 Some agents, such as nifedipine, can cause a tachycardia, whereas diltiazem and verapamil reduce heart rate, actions that might influence their clinical effects. In this overview, we present the effects oftreatment for each outcome of interest; firstly, for the overall data, secondly, by each agent, and, thirdly, by category of agents that share some common ancillary properties.
Methods
The methods are similar to those described and used previously. 3 The intent was to obtain data on mortality and, when relevant, initial or recurrent myocardial infarction and infarct size from each completed, published or unpublished, randomised controlled trial of any calcium channel blocking agent in patients with suspected or definite myocardial infarction or in patients with unstable angina. Our method was to scan the journals, both by a formal computer aided search and by an informal search for studies that were known to ourselves or to coworkers; to scan the reference lists of the published papers; and to inquire about uncompleted or completed but unpublished trials from colleagues. When possible if the data thus obtained did not include all randomised patients or did not include certain end points (such as reinfarction) of particular interest we sought additional details by correspondence, generally with the principal investigators. Data on outcome from the different trials were combined by the Mantel-Haenszel method.3 The analyses were performed separately for each agent, for the short term and long term trials separately, and for the trials in total.
The underlying principle was that patients allocated to active treatment in one trial were compared directly only with those allocated to control in the same trial and not with patients in any other trial. Therefore, differences in the characteristics of patients between trials did not matter as long as the patients were broadly similar (for example, suspected acute myocardial infarction). For each trial the number of events observed in the treated group was contrasted with the number that would have been expected if treatment had no effect. If treatment was of no benefit differences between the observed and the expected events would differ only randomly from zero. A beneficial treatment effect with fewer events in the actively treated group would result in a negative value for observed minus expected, while a harmful treatment would result in a positive value. In a single trial this tendency might be obscured by chance, but when several individual trials are combined to give a grand total of all the values such chance variations tend to be averaged out.
Determination of the effects of treatment from the grand total assumes that information is available from all trials of an unbiased subsample. It does not, however, assume that the treatment effect is the same in different trials but rather that this effect will tend to be in the same direction in most trials. In three trials mortality was lower in the group allocated to receive calcium channel blockers compared with those allocated to the control group; in five trials no difference was found; and in 13 trials mortality was higher. None of these individual differences was significant. Overall, there were 873 deaths in 8870 patients (9 8%) allocated to active treatment compared with 825 deaths among 8889 controls (9 3%) during the scheduled trial period (typical odds of death was increased by 6%, 95% confidence interval -4% to 18%).
Whether treatment was started early and continued short term or long term or was started later and continued long term did not materially influence the outcome (table III, figure) . A small but non-significant increase in mortality in patients allocated calcium channel blockers was observed in all three categories of trials. 
Infarct size
Data on enzymatically estimated size of infarct were available from 13 of the 16 trials in which treatment started within 24 hours (table V). Three trials reported only peak creatine kinase activities, while 10 trials measured peak or cumulative activities of the MB isomer of creatine kinase. Enzyme activities were, with one exception,9 reported only in patients developing a definite myocardial infarction. In most of the trials data were missing for several patients, probably because of difficulties in obtaining blood samples. In one large trial only a subset of the patients was studied."' 3 In five trials the enzyme release was lower in the treated group, in seven trials it was higher, and in one no difference was found. In one small open trial the difference was significant (p<0005).4
Reinfarction
Because of the difficulty in differentiating between an extension of the first infarction and reinfarction five early treatment trials with a study period of only 24-48 hours were excluded from this analysis.48 t1420 Reinfarction data were available from 11 of the 17 remaining trials for a total of 13 900 patients (table VI, figure) . In six trials the rate of reinfarction was lower in patients allocated to calcium channel blockers than in the control group and in four trials it was higher. One trial reported no reinfarctions in either group.'9 In one trial the lower number of reinfarctions in the treated group almost reached nominal significance (two tailed p=006)." Overall, 292 of 6939 patients (4-2%) allocated to calcium channel blockers suffered a nonfatal reinfarction compared with 317 of 6967 patients (4-6%) in the control group (typical odds reduction of 9%; 95% confidence interval -24% to 7%).
Results by study drug
Moderately large numbers of patients have been studied with each drug except tiapamil. IV, figure) . With both these agents the proportion of patients developing myocardial infarction was similar in patients allocated to calcium channel blockers and controls (typical odds ratios=0-99 and 0-98, respectively).
Data on reinfarction were available for 3465 patients in trials of verapamil, for 7325 patients in trials of nifedipine, and 3117 patients in trials of diltiazem (table VII) . Although there seemed to be a slight trend towards fewer reinfarctions in patients treated with verapamil and diltiazem, there was a non-significant increase compared with controls in the nifedipine trials. There was no statistical evidence of heterogeneity in the effects of these agents on reinfarctions, though the data were consistent with the possibility that agents that reduce heart rate (diltiazem and verapamil) might reduce the risk of reinfarction (167/ 3295 in the treated group compared with 208/3287 in the control group; odds reduction of 20%). This hypothesis is derived after viewing the data and should therefore be interpreted with caution and specifically examined in future trials.
UNSTABLE ANGINA TRIALS Table II shows the results on development of myocardial infarction and deaths in the six trials of unstable angina. The largest trial was stopped early because of a trend towards more non-fatal myocardial mortality in the calcium blocker group was found mainly in the nifedipine trials, no significant heterogeneity was seen in the results ofdifferent drugs on this or any of the other end points. As the power to detect interactions even in the pooled data is probably low only large interactions can be excluded. Examination of the effect of treatment on several end points in a large number of trials may lead to spurious findings by chance, which may be nominally significant. Moreover, examination of the effects of treatment in multiple subgroups within each trial further increases the possibility of observing extreme results by chance. In several trials attempts have been made to identify subgroups in which treatment may have been harmful and others in which it may have been beneficial. In the multicentre diltiazem postinfarction trial a significant bidirectional interaction was claimed-a favourable but non-significant trend in those;without pulmonary congestion (odds ratio 0 79; 95% confidence interval 0 57 to 1*10)-whereas a "significant" adverse effect was observed in those with pulmonary congestion (odds ratio 1 85; 1 24 to 275). 25 
